Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma

The recommended phase II dose of paclitaxel 180 mg m(−2) given as a 3-h infusion followed by nedaplatin 100 mg m(−2) in a 1-h infusion every 3–4 weeks was determined in 52 chemo-naive patients with unresectable squamous cell carcinoma (SCC), with a promising response rate for lung SCC of 55%....

Descripción completa

Detalles Bibliográficos
Autores principales: Sekine, I, Nokihara, H, Horiike, A, Yamamoto, N, Kunitoh, H, Ohe, Y, Tamura, T, Kodama, T, Saijo, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409664/
https://www.ncbi.nlm.nih.gov/pubmed/15026789
http://dx.doi.org/10.1038/sj.bjc.6601700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409664/
https://www.ncbi.nlm.nih.gov/pubmed/15026789
http://dx.doi.org/10.1038/sj.bjc.6601700

Ejemplares similares